Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Down 56.3% in May

Pasithea Therapeutics Corp. (NASDAQ:KTTA) was the target of a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 236,000 shares, a decrease of 56.3% from the May 15th total of 540,000 shares. Approximately 3.5% of the company’s shares are sold short. Based on an average daily trading volume, of 5,970,000 shares, the short-interest ratio is currently 0.0 days.

Pasithea Therapeutics Stock Down 1.4%

Shares of KTTA traded down $0.01 during trading on Monday, reaching $0.77. The company’s stock had a trading volume of 345,243 shares, compared to its average volume of 2,070,466. The company has a fifty day moving average of $1.15 and a two-hundred day moving average of $1.72. The company has a market cap of $5.77 million, a price-to-earnings ratio of -0.07 and a beta of 0.33. Pasithea Therapeutics has a twelve month low of $0.72 and a twelve month high of $7.50.

Pasithea Therapeutics (NASDAQ:KTTA) last posted its earnings results on Thursday, May 15th. The company reported ($1.61) earnings per share (EPS) for the quarter.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.